The critical need for alternative antiretroviral formulations, and obstacles to their development

Journal of Infectious Diseases

Volumn 204, Issue 5, 2011, Pages 669-674

  Swindells, Susan ^a   Flexner, Charles ^b   Fletcher, Courtney V ^a   Jacobson, Jeffrey M ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; FOSCARNET; IBALIZUMAB; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PRO 140; RALTEGRAVIR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

ADULT; ARTICLE; BRONCHUS FISTULA; CASE REPORT; CLINICAL FEATURE; DRUG APPROVAL; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RESEARCH; ESOPHAGITIS; GASTROINTESTINAL ENDOSCOPY; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; ODYNOPHAGIA; PRIORITY JOURNAL; SINGLE DRUG DOSE; STENT; STOMACH TUBE;

ANIMALS; ANTI-RETROVIRAL AGENTS; DOSAGE FORMS; HIV INFECTIONS; HUMANS; INFUSIONS, PARENTERAL; MALE; MIDDLE AGED;

EID: 80051753353     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir370     Document Type: Article

References (28)

1. Clarkson JE, Worthington HV, Furness S, McCabe M, Khalid T, Meyer S. Interventions for treating oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev 2010; (8):CD001973.
2. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. http://www.aidsinfo.nih.gov. Accessed 4 October 2010.
3. Guidelines for the use of antiretroviral agents in pediatric HIV infection. http://www. aidsinfo.nih.gov. Accessed 22 October 2010.
4. Zolopa A, Andersen J, Powderly W, et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009; 4:e5575.
5. Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321-333
6. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov. Accessed 4 October 2010.
7. Darwich L, Esteve A, Ruiz L, Bellido R, Clotet B, Martinez-Picado J. Variability in the plasma concentration of efavirenz and nevirapine is associated with genotypic resistance after treatment interruption. Antivir Ther 2008; 13:945-951
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331:1173-1180 (Pubitemid 24331334)
9. King JR, McCall M, Cannella A, Markiewicz MA, James A, Acosta EP. Assessment of bioequivalence of tenofovir, emtricitabine and efavirenz (Atripla) fixed dose combination tablet compared with a compounded oral liquid formulation derived from the tablet [abstract 605]. In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: CROI, 2010.
10. Diep H, Best BM, Capparelli EV, Rossi SS, et al. Pharmacokinetics of lopinavir/ritonavir crushed versus whole tablets in children [abstract 877]. In: 17th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA: CROI, 2010.
11. Best B, Rieg G, Sun S, et al. Increased lopinavir (LPV) concentrations on once-daily tablets as compared to capsules and liquid formulations [abstract 766a]. 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA: CROI, 2008.
12. World Health Organization. Antiretroviral therapy for HIV infection in infants and children: towards universal access, recommendations for a public health approach. 2010 revision. http://www.who.int/hiv/pub/paediatric/ infants2010/en/index.html. Accessed 4 October 2010.
13. Kim DD, Chien YW. Transdermal delivery of dideoxynucleoside-type anti-HIV drugs. 2. The effect of vehicle and enhancer on skin permeation. J Pharm Sci 1996; 85: 214-219 (Pubitemid 26055804)
14. Kuritzkes DR, Jacobson J, Powderly WG, et al. Antiretroviral activity of the anti-CD4 monoclonal antibody TNX-355 in patients infected with HIV type 1. J Infect Dis 2004; 189:286-291 (Pubitemid 38147253)
15. Jacobson JM, Kuritzkes DR, Godofsky E, et al. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother 2009; 53:450-457
16. Norris D, Morales J, Gathe J. Phase 2 efficacy and safety of the novel entry inhibitor, TNX-355, in combination with optimized background regimen (OBR). In: Programme and abstracts of the 16th International AIDS Conference. Toronto, ON, Canada: Internal AIDS Conference, 2006.
17. Murga J, Franti M, Pevear DC, Maddon PJ, Olson WC. Potent antiviral synergy between monoclonal antibody and small molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006; 50:3289-3296 (Pubitemid 44527500)
18. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198: 1345-1352
19. Jacobson JM, Thompson MA, Lalezari JP, et al. Anti-HIV-1 activity of weekly or bi-weekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. J Infect Dis 2010; 201:1481-1487
20. van't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042-2050
21. van 't Klooster G, Verloes R, Baert L, et al. Long-acting TMC278, a parenteral depot formulation delivering therapeutic NNRTI concentrations in preclinical and clinical settings [abstract 134]. In: 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA: CROI, 2008.
22. Nowacek AS, McMillan J, Miller R, Anderson A, Rabinow B, Gendelman HE. Nanoformulated antiretroviral drug combinations extend drug release and antiretroviral responses in HIV-1-infected macrophages: implications for neuroAIDS therapeutics. J Neuroimmune Pharmacol 2010; 5:592-601.
23. Di Gianvincenzo P, Marradi M, Martinez-Avila OM, et al. Gold nanoparticles capped with sulfate-ended ligands as anti-HIV agents. Bioorg Med Chem Lett 2010; 20: 2718-2720
24. Dikinson C, Attawell K, Druce N. Progress on scaling up integrated services for sexual and reproductive health and HIV. Bull World Health Organ. 2009; 87:846-851
25. Asmuth DM, Murphy RL, Rosenkranz SL, et al. Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J Infect Dis 2010; 201:1686-1696
26. Devianne-Garrigue I, Pellegrin I, Denisi R, et al. Foscarnet decreases HIV-1 plasma load. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18:46-50.
27. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy by patients with human immunodeficiency virus infection. Ann Intern Med 2000; 133: 21-30. (Pubitemid 30432540)
28. Conti RM, Meltzer DO, Ratain MJ. Nonprofit biomedical companies. Clin Pharmacol Ther. 2008; 84:194-197